PM Frequencies of Major CYPs in Asians and Caucasians

References

• Aithel G. P., Day C. P., Leathart J. B. S., Daly A. K. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics 2000; 10: 511–518
   Google Scholar
• Ariyoshi N., Takahashi Y., Miyamoto M., Umetsu Y., Daigo S., Tateishi T., Kobayashi S., Mizorogi Y., Loriot M.-A., Stucker I., Beaune P., Kinoshita M., Kamataki T. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C. Pharmocogenetics 2000; 10: 687–693
   Google Scholar
• Evans W. E., Relling M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487–491
   Google Scholar
• Griese E.-U., Ilett K. F., Kitteringham N. R., Eichelbaum M., Powell H., Spargo R. M., LeSouef P. N., Musk A. W., Minchin R. F. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia. Pharmacogenetics 2001; 11: 69–76
   Google Scholar
• Guengerich F. P., Miller G. P., Hanna I. H., Martin M. V., Leger S., Black C., Chauret N., Silva J. M., Trimble L. A., Yergey J. A., Nicoll-Griffith D. A. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 2002; 41: 11025–11034
   Google Scholar
• Hirano Y., Uehara M., Saeki K., Kato T., Takahashi K., Mizutani T. The influence of quinolines on coumarin 7-hydroxylation in bovine liver microsomes and human CYP2A6. J. Health Sci. 2002; 48: 118–125
   Google Scholar
• Hiroi T., Imaoka S., Funae Y. Dopamine formation from Tyramine by CYP2D6 Biochem. Biophys. Res. Commun. 1998; 249: 838–843
   Google Scholar
• Hsien K.-P., Lin Y.-Y., Cheng C.-L., Lai M.-L., Lin M.-S., Siest J.-P., Huang J.-D. Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos. 2001; 29: 268–273
   Google Scholar
• Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab. Dispos. 2001; 29: 570–573
   Google Scholar
• Kaneko A., Kaneko O., Taleo G., Bjorkman A., Kabayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997; 349: 921–922
   Google Scholar
• Kaneko A., Bergqvist Y., Taleo G., Kabayakawa T., Ishizaka T., Bjorkman A. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics 1999a; 9: 317–326
   Google Scholar
• Kaneko A., Lum J. K., Yaviong J., Takahashi N., Ishizaki T., Bertilsson L., Kabayakawa T., Bjorkman A. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. Pharmacogenetics 1999b; 9: 581–590
   Google Scholar
• Kubota T., Chiba K., Iga T. Frequency distribution of CYP2C19 and CYP2C9 mutant-alleles in several different populations. Xenobio. Metabol. Dispos. 2001; 16: 69–74, (in Japaneese)
   Google Scholar
• Kwon J. T., Nakajima M., Chai S., Yom Y.-K., Kim H.-K., Yamazaki H., Sohn D.-R., Yamamoto T., Kuroiwa Y., Yokoi T. Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics 2001; 11: 317–323
   Google Scholar
• Miyamoto M., Umetsu Y., Dosaka-Akita H., Sawamura Y., Yokota J., Kunitoh H., Nemoto N., Sato K., Ariyoshi N., Kamataki T. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem. Biophys. Res. Commun. 1999; 261: 658–660
   Google Scholar
• Nakajima M., Yokoi T., Mizutani M., Kinoshita M., Funayama M., Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. 1999; 125: 803–808
   Google Scholar
• Nelson D., Kamataki T., Waxman D. J., Guengerich F. P., Estabrook R. W., Feyereisen R., Gonzalez F. J., Coon M. J., Gunsalus I. C., Gotoh O., Okuda K., Nebert D. W. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol. 1993; 12: 1–51
   Google Scholar
• Nielsen T. L., Rasmussen B. B., Flinois J.-P., Beaune P., Brosen K. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-450 3A4 activity in human liver microsomes. J. Pharmcol. Exp. Ther. 1999; 289: 31–37
   Google Scholar
• Omura T. Forty years of cytochrome P450. Biochem. Biophys. Res. Commun. 1999; 266: 690–698
   Google Scholar
• Omura T., Sato R. The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem. 1962; 237: 1375–1376
   Google Scholar
• Osacarson M., McLellan R. A., Gullstein H., Agundez J. A. G., Benitez J., Rautio A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Identification and characterization of novel polymorphisms in the CYP2A locus: implication for nicotine metabolism. FEBS Lett. 1999a; 460: 321–327
   Google Scholar
• Oscarson M., McLellan R. A., Gullstein H., Yue Q.-Y., Lang M. A., Bernal M. L., Sinues B., Hirvonen A., Raunio H., Pelkonen O., Ingelman-Sundberg M. Characterization and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999b; 448: 105–110
   Google Scholar
• Ozdemir V., Kalow W., Tang B.-K., Paterson A. D., Walker S. E., Endrenyi L., Kashuba A. D. M. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 2000; 10: 373–388
   Google Scholar
• Ramamoorthy Y., Tydale R. F., Sellers E. M. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics 2001; 11: 477–487
   Google Scholar
• Sachse C., Brockmoller J., Bauer S., Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic concequences. Am. J. Hum. Genet. 1997; 60: 284–295
   Google Scholar
• Shimada T., Tsumura F., Yamazaki H., Guengerich F. P., Inoue K. Characterization of (+)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 2001; 11: 143–156
   Google Scholar
• Sueyoshi T., Negishi M. Phenobarbital response elements of cytochrome P450 genes and nuclear receptors. Annu. Rev. Pharmacol. Toxicol. 2001; 41: 123–143
   Google Scholar
• Takahashi K., Tainaka H., Kobayashi K., Yasumori T., Hosokawa M., Chiba K. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95–104
   Google Scholar
• Wei P., Zhang J., Egan-Hafley M., Liang S., Moore D. D. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature 2000; 407: 920–923
   Google Scholar
• Wrighton S. A., Ring B. J. Predicting drug interactions and pharmocokinetics variability with in vitro methods: the olazapine experience. Drug Metab. Rev. 1998; 30: 15–28
   Google Scholar
• Xie W., Barwick J. L., Downes M., Blumberg B., Simon C. M., Nelson M. C., Neuschwander-Tetri B. A., Brunt E. M., Guzelian P. S., Evans R. M. Humanized xenobiotic response in mice expressing nuclear receptor SXR. Nature 2000; 406: 435–439
   Google Scholar